EUVIMEDEUVIMED entdecken
Crossref

Exploring Predictive Biomarkers of Relapse in Ulcerative Colitis: A Proteomics Approach

Arash Assadsangabi iD, Caroline A Evans, Bernard M Corfe, Alan J Lobo

Inflammatory Bowel Diseases · 2024

DOI: 10.1093/ibd/izad241 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2024. Verfasst von Arash Assadsangabi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Gastroenterology Research Group, Department of Oncology and Metabolism, Medical School, University of Sheffield, Sheffield, United Kingdom. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Proteomics, Biomarkers, Recurrence. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 77 Literaturangaben. Gefördert von: Bardhan Research and Education Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and aims Risk stratification of subjects with a history of inflammatory bowel disease (IBD) into those likely to relapse and those who will remain quiescent continues to be a significant challenge. The aim of this study was to investigate whether certain proteomic signature profiles or biomarkers during remission are associated with future disease relapse in patients with ulcerative colitis (UC).

Methods

Endoscopic rectal samples from patients with UC in clinical, endoscopic, and histological remission at index endoscopy were collected, as well as samplers from normal control individuals. The patients were stratified to early relapsers (ERs) if they developed clinical signs of UC flare within 6 months of index endoscopy or nonrelapsers (NRs) if there was no relapse after 36 months of follow-up. The pooled rectal samples from ERs, NRs, and control individuals were subjected to nano-liquid chromatography and tandem mass spectrometry as per standard iTRAQ (isobaric tags for relative and absolute quantitation) workflow methodology. Selected proteomics-yielded candidates were subjected to orthogonal validation via immunoblotting, in a biomarker discovery exercise.

Results

Sixty-one patients were included, of whom 8 had clinical relapse within 6 months from the index endoscopy, and 43 patients had no clinical symptoms of relapse within the 36-month follow-up period. Ten patients who had clinical signs of relapse between 6 and 36 months were excluded. Seventeen control individuals were also included. Soluble proteomics analyses between ERs, NRs, and control individuals revealed a series of upregulated and downregulated proteins. Following orthogonal validation, upregulated TRX (P = .001) and IGHA1 (P = .001) were observed in ERs relative to NRs.

Conclusions

Several novel candidate tissue biomarkers have been identified in this study, which could discriminate patients with UC at risk of early relapse from those in long-term sustained remission. Our findings may pave the way for pre-emptive UC disease monitoring and therapeutic decision making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeProteomicsBiomarkersRecurrenceHumansMaleFemaleAdultMiddle AgedCase-Control StudiesFollow-Up StudiesPrognosisYoung AdultTandem Mass Spectrometry

Stichwörter der Autor:innen

biomarkerinflammatory pathwayproteomicsulcerative colitis

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Molecular Gastroenterology Research Group, Department of Oncology and Metabolism, Medical School, University of Sheffield, Sheffield, United Kingdom.
  • Gastroenterology Unit, Royal Hallamshire Hospital, Sheffield, United Kingdom.
  • Gastroenterology Department, Salford Royal NHS Foundation Trust, Salford, United Kingdom.
  • Faculty of Biology, Medicine and Health, School of Medical Sciences, University of Manchester, Manchester, United Kingdom.
  • Biological and Systems Engineering Group, ChELSI Institute, Department of Chemical and Biological Engineering, University of Sheffield, Sheffield, United Kingdom.

ORCID-Profile: Arash Assadsangabi

Förderung

  • Bardhan Research and Education Trust

Zitieren

APA

Assadsangabi, A., Evans, C. A., Corfe, B. M., & Lobo, A. J. (2024). Exploring Predictive Biomarkers of Relapse in Ulcerative Colitis: A Proteomics Approach. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izad241

Vancouver

Assadsangabi A, Evans CA, Corfe BM, Lobo AJ. Exploring Predictive Biomarkers of Relapse in Ulcerative Colitis: A Proteomics Approach. Inflammatory Bowel Diseases. 2024. doi:10.1093/ibd/izad241

BibTeX
@article{Assadsangabi2024,
  author = {Assadsangabi, Arash and Evans, Caroline A and Corfe, Bernard M and Lobo, Alan J},
  title = {Exploring Predictive Biomarkers of Relapse in Ulcerative Colitis: A Proteomics Approach},
  journal = {Inflammatory Bowel Diseases},
  year = {2024},
  doi = {10.1093/ibd/izad241}
}
Kostenlos starten →